ALDH1A3 and central nervous system cancer: They show that ALDH2, ALDH5A1, ALDH6A1, ALDH1L2, ALDH1B1, ALDH18A1, ALDH1A1, ALDH8A1, and ALDH1B1 expressions are higher in isocitrate dehydrogenase (IDH) mutant gliomas and demonstrated to be favorable factors for patients with low‐risk scores, whereas ALDH16A1, ALDH3B1, ALDH3A1, ALDH7A1, ALDH1A3, ALDH1L1, and ALDH1A2 expressions are increased in IDH wildtype and are associated with a worse prognosis risk.204